Retrophin appoints board member
This article was originally published in Scrip
Executive Summary
Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of rare diseases, has named Jeffrey A Meckler to its board of directors as a fourth independent director. Mr Meckler is currently a director of QLT an ultra-orphan ophthalmic biotechnology company based in Canada, as well as the managing director of The Andra Group, a life sciences consulting firm.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports